August 19, 2021
2 min watch
Save
VIDEO: Molecular tumor board ‘incredibly well received’ at ILCC
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this vide, David R. Gandara, MD, spoke with Healio about the molecular tumor board discussion at the International Lung Cancer Congress.
According to Gandara, director of the thoracic oncology program at UC Davis Comprehensive Cancer Center and chief medical officer for the International Society of Liquid Biopsy, ILCC incorporated audience response devices for all sessions, including the molecular tumor board.
“We would step by step ask our attendees – so this is, altogether, probably 400 people – ‘what would you do in this situation?’”
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Gandara reports receiving institutional research grants from Amgen, AstraZeneca, Genentech and Merck; and serving as a consultant or on advisory boards for AstraZeneca (institutional), Roche-Genentech (institutional), Guardant Health (institutional), Inivata, IO Biotech (institutional), Lilly, Merck, Novartis and Oncocyte (institutional)
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.